CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
The biotech industry is currently undergoing a wider financial upheaval after the collapse of Silicon Valley Bank (SVB), which was…
All articles by Fiona Barry
Fiona Barry
Fiona Barry is an Associate Editor responsible for GlobalData PharmSource’s editorial content. She previously worked as an investigative journalist reporting scoops on drug trials, contract pharma, rare diseases, and women’s health.
-
-
CMO Moves: Regulatory catalysts for drug manufacturing- February
Manufacturing a drug therapy usually involves several different stakeholders. Contract manufacturing organizations (CMOs) not only produce the active pharmaceutical ingredient…
-
Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The…
-
CMO Moves: Regulatory catalysts for therapy manufacturing -January
In the first 2023 edition of the CMO Moves monthly series, Pharmaceutical Technology explores recent news stories on regulatory and…
-
CMO Moves: Regulatory catalysts for drug manufacturing-December
In this last 2022 edition of the series, which started in June, Pharmaceutical Technology is tracking major trial announcements and…
-
CMO Moves: Regulatory catalysts for drug manufacturing-November
Crossing the approval hurdle for a new drug is a big milestone for pharmaceutical companies. However, efficiently manufacturing the drug…
-
CMO Moves: Regulatory catalysts for drug manufacturing-October
As the pharmaceutical industry, along with the rest of the corporate sector, enters the last quarter of the year, all…
-
CMO Moves: Regulatory catalysts for drug manufacturing-September
In recent weeks, several regulatory decisions on Covid-19 vaccines and boosters have come through that are expected to spur vaccine…
-
CMO Moves: Regulatory catalysts for drug manufacturing—August
Pharmaceutical and biotech companies live and die by regulatory decisions on their therapies. These verdicts not only impact the company…
-
California’s low-cost insulin plans receive $100m manufacturing boost
Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to…